Clinical-stage medtech developing the CaverSTIM neurostimulation implant for erectile dysfunction.
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Series A Comphya closed an oversubscribed CHF 7.5M Series A to fund a US pilot study of its CaverSTIM erectile-dysfunction implant. | $9.4M |
Data is community-curated and may be incomplete.